Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066622 · ClinicalTrials.gov registry record · Phase 4
Olanzapine for Acute Headaches
A Phase 4 study of Headache, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT03066622: Completed Phase 4 study of Headache, sponsored by HealthPartners Institute.
NCT03066622 is a Phase 4 study of Headache that has completed, run by HealthPartners Institute. The registered enrollment target is 122 participants, below the 152-participant average among 35 other Headache trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066622, a Phase 4 study of Headache, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.
Primary Outcome
Change in patient reported pain score from baseline using the Numeric Pain Rating Scale (PNRS) Minimum score = 0 Maximum score = 10 Lower score indicates lower pain level, with zero indicating no pain and 10 indicating the worst pain imaginable.
Conditions Studied
Interventions
- DRUG Standard of Care as per attending physician
- DRUG 5mg rapidly dissolving olanzapine
Study Locations (1)
Minnesota
- Regions Hospital - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-05-20 |
| Phase | Phase 4 |
What the finished NCT03066622 record still lists
NCT03066622 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 152-participant average among 35 other Headache trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Headache appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care as per attending physician is the first listed.
NCT03066622 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03066622 about?
NCT03066622 is a clinical study titled "Olanzapine for Acute Headaches". This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular med...
What is the current status of trial NCT03066622?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2016-07. Estimated completion is 2018-05-20.
What conditions does trial NCT03066622 study?
This clinical trial studies the following conditions: Headache.
What interventions are being tested in trial NCT03066622?
The interventions under investigation include: Standard of Care as per attending physician (DRUG), 5mg rapidly dissolving olanzapine (DRUG).
Who is sponsoring clinical trial NCT03066622?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03066622 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Headache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03066622's enrollment target sits among peer trials
122 12th of 35 higher than 23 of 35 other Headache trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Headache trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
RECRUITING · Phase 4
-
Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache
COMPLETED · Phase 4
-
Concussion Recovery and Support Program
RECRUITING · NA
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
RECRUITING
-
Puberty, Testosterone, and Brain Development
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia